Industries > Pharma > Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
Forecasts by Category (PD1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Cytokines Targets, Immuno Adjuvants, Immunomodulators), by PD1 Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo)), by PD-L1 Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), by CTLA-4 Inhibitors (Ipilimumab (Yervoy)), by Immuno Adjuvants (Imiquimod, Poly ICLC (Hiltonol)), by Immunomodulators (Pexidartinib (Turalio)), by Cytokines Targets (Aldesleukin, GM-CSF, Interferon Alfa-2a, Interferon Alfa-2b (Intron A®), Peginterferon alfa-2b (Sylatron®/PEGIntron®)), by Application (Lung Cancer Treatment, Renal Cancer Treatment, Blood Cancer Treatment, Bladder Cancer Treatment, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios
The Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
New Products/Therapy Launch Are Gaining Tractions in the Global Market
To distinguish their product offerings, new entrants into the oncology industry may use a variety of strategies. One strategy is to be first-in-class with a novel mechanism of action (MOA); another is to focus on an indication with a strong unmet need, thus providing a valuable new therapeutic choice for patients with few choices.
Increasing Support from FDA in the Approval Procedures
Currently, the FDA has licenced two anti-PD-1 antibodies: pembrolizumab and nivolumab. These medications, such as ipilimumab, were initially approved to treat advanced-stage melanomas but have since been approved to treat a variety of cancers. The third group of FDA-approved ICIs is antibodies against PD-L1. Urothelial carcinoma, non-small cell lung cancer (NSCLC), and Merkel cell carcinoma are treated with three anti-PD-L1 antibodies: atezolizumab, durvalumab, and avelumab. Anti-PD-1 and anti-PD-L1 antibodies have outperformed anti-CTLA-4 antibodies in clinical trials due to a combination of superior clinical efficacy and tolerability
What Are These Questions You Should Ask Before Buying A Market Research Report?
• How is the checkpoint inhibitors for treating cancer market evolving?
• What is driving and restraining the checkpoint inhibitors for treating cancer market?
• How will each checkpoint inhibitors for treating cancer submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2031?
• How will the market shares for each checkpoint inhibitors for treating cancer submarket develop from 2021 to 2031?
• What will be the main driver for the overall market from 2021 to 2031?
• Will leading checkpoint inhibitors for treating cancer markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2031 and which geographical region will lead the market in 2031?
• Who are the leading players and what are their prospects over the forecast period?
• What are the checkpoint inhibitors for treating cancer projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2031?What are the implication of checkpoint inhibitors for treating cancer projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the checkpoint inhibitors for treating cancer market?
• Where is the checkpoint inhibitors for treating cancer market heading? And how can you ensure you are at the forefront of the market?
• What can be the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path? C-suite?
You need to discover how this will impact the checkpoint inhibitors for treating cancer market today, and over the next 10 years:
• Our 612-page report provides 447 tables and 448 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analyse of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the checkpoint inhibitors for treating cancer market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
To access the data contained in this document please email contactus@visiongain.com
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising checkpoint inhibitors for treating cancer prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Category
• PD1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Cytokines Targets
• Immuno Adjuvants
• Immunomodulators
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by PD1 Inhibitors
• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)
• Cemiplimab (Libtayo)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by PD-L1 Inhibitors
• Atezolizumab (Tecentriq)
• Avelumab (Bavencio)
• Durvalumab (Imfinzi)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by CTLA-4 Inhibitors
• Ipilimumab (Yervoy)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Immuno Adjuvants
• Imiquimod
• Poly ICLC (Hiltonol)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Immunomodulators
• Pexidartinib (Turalio)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Cytokines Targets
• Aldesleukin
• GM-CSF
• Interferon Alfa-2a
• Interferon alfa-2b (Intron A)
• Peginterferon alfa-2b (Sylatron/PEG-Intron)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Application
• Lung Cancer Treatment
• Renal Cancer Treatment
• Blood Cancer Treatment
• Bladder Cancer Treatment
• Other Application
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:
• North America Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• U.S. Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Canada Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Mexico Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Europe Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• Germany Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Spain Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• United Kingdom Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• France Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Italy Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Europe Market Forecast & COVID Impact Analysis
• Asia Pacific Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• China Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Japan Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• India Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Australia Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• South Korea Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Asia Pacific Market Forecast & COVID Impact Analysis
• LAMEA Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• Brazil Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Turkey Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• South Africa Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• UAE Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Latin America, Middle East and Africa
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• A Seagen Inc.,
• Agenus Inc. (Agenus)
• Agilent Technologies, Inc.
• AbbVie Inc. (AbbVie)
• Xencor, Inc.
• Ono Pharmaceutical Co., Ltd.
• Sanofi SA
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc. (Pfizer)
• Roche Holding AG (Roche)
• Merck & Co., Inc.
• Incyte Corporation
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Clovis Oncology, Inc.
• Heptares Therapeutics Ltd.
Overall world revenue for Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 in terms of value the market will surpass US$xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market report helps you?
In summary, our 610+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for 4 regional and 20 key national markets – See forecasts for the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: Forecasts by Category (PD1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Cytokines Targets, Immuno Adjuvants, Immunomodulators), by PD1 Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo)), by PD-L1 Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), by CTLA-4 Inhibitors (Ipilimumab (Yervoy)), by Immuno Adjuvants (Imiquimod, Poly ICLC (Hiltonol)), by Immunomodulators (Pexidartinib (Turalio)), by Cytokines Targets (Aldesleukin, GM-CSF, Interferon Alfa-2a, Interferon Alfa-2b (Intron A®), Peginterferon alfa-2b (Sylatron®/PEGIntron®)), by Application (Lung Cancer Treatment, Renal Cancer Treatment, Blood Cancer Treatment, Bladder Cancer Treatment, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Introduction to Checkpoint Inhibitors Market
1.2 Global Checkpoint Inhibitors Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Checkpoint Inhibitors Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered by This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Visiongain Reports
1.13 About Visiongain
2 Executive Summary
3 Checkpoint Inhibitors Industry Structure
3.1 Overview
3.1.1 Inhibitory Immune Checkpoint Targets
3.1.2 Immunometabolic Modulatory Targets
3.1.3 CAR-T Cells
4 Global Market Dynamics
4.1 Current Trends in the Global Market
4.2 Market Driving Factors
4.2.1 Peripheral Immune Responses Are Critical in Achieving Favourable Clinical Outcomes
4.2.2 New Products/Therapy Launch Are Gaining Tractions in the Global Market
4.2.3 Increasing Support from FDA in the Approval Procedures
4.3 Market Restraining Factors
4.3.1 Most Patients and Cancers Do Not Respond to Checkpoint Inhibitor Therapies
4.3.2 Immune-Related Adverse Events Occurred, Restraining Further Research
4.3.3 An Increased Risk of Thromboembolism
4.4 Opportunities in the Global Market
4.4.1 Unprecedented Advances in Cancer Immunotherapy
4.4.2 Unmet Medical Needs
4.4.3 New Combinations Therapies Creating New Opportunities
4.5 Challenges in the Global Market
4.5.1 Lack of Understanding in Regards to Checkpoint Inhibitors Mechanisms
4.5.2 Resistance to Immune Checkpoint Inhibitors
4.5.3 Whether irAE Presentation Correlates with ICI efficacy is a Challenge
5 Global Checkpoint Inhibitors Market Analysis
5.1 Global Market Outlook
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario
5.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Market Breakdown by Category
6.1 Segment Overview
6.1.1 PD-1 inhibitor:
6.1.2 PD-L1 Inhibitors:
6.1.3 CTLA-4 Inhibitors:
6.1.4 Cytokines Targets:
6.1.5 Immuno Adjuvants
6.1.6 Immunomodulators
6.1.7 Pre-COVID-19 Market Scenario
6.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Market Breakdown by PD1 Inhibitors
7.1 Segment Overview
7.1.1 Introduction to PD-1/PD-L1 Agents
7.1.2 Pembrolizumab (Keytruda), Merck & Co.
7.1.3 Nivolumab (Opdivo), BMS
7.1.4 Atezolizumab (Tecentriq), Genentech
7.1.5 Cemiplimab (Libtayo), Regeneron/Sanofi
7.1.6 Pre-COVID-19 Market Scenario
7.1.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7.2 Global Market Breakdown by PD-L1 Inhibitors
7.2.1 Avelumab (Bavencio), Merck KGaA/Pfizer
7.2.2 Durvalumab (Imfinzi), AstraZeneca
7.2.3 Pre-COVID-19 Market Scenario
7.2.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Market Breakdown by CTLA-4 Inhibitors
8.1 Segment Overview
8.1.1 Pre-COVID-19 Market Scenario
8.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Market Breakdown by Cytokines Target
9.1 Segment Overview
9.1.1 Pre-COVID-19 Market Scenario
9.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Market Breakdown by Immuno Adjuvants
10.1 Segment Overview
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Market Breakdown by Immuno Modulators
11.1 Segment Overview
11.2 Pre-COVID-19 Market Scenario
11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 Global Market Breakdown by Application
12.1 Segment Overview
12.1.1 Lung Cancer Treatment
12.1.2 Renal Cancer Treatment
12.1.3 Blood Cancer Treatment
12.1.4 Bladder Cancer Treatment
12.2 Pre-COVID-19 Market Scenario
12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Global Checkpoint Inhibitors Market by Region
13.1 Regional Market Size Estimation and Forecast
13.1.1 Pre-COVID-19 Market Scenario
13.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 North America Checkpoint Inhibitors Market Analysis
14.1 North America Market Outlook
14.2 North America Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Country Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 North America Market Breakdown by Category
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 North America Market Breakdown by PD-1 Inhibitors
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 North America Market Breakdown by PD-L1 Inhibitors
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 North America Market Breakdown by CTLA-4 Inhibitors
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 North America Market Breakdown by Cytokines Target
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 North America Market Breakdown by Application
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 North America Market Breakdown by Immuno Adjuvants
14.10.1 Pre-COVID-19 Market Scenario
14.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 North America Market Breakdown by Immunomodulators
14.11.1 Pre-COVID-19 Market Scenario
14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 US Checkpoint Inhibitors Market Analysis
14.12.1 Clinical Use of Checkpoint Inhibitors is Growing Rapidly in the US
14.12.2 Acceptance of Checkpoint Inhibitors for Treating Cancer
14.12.3 Pre-COVID-19 Market Scenario
14.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 Canada Checkpoint Inhibitors Market Analysis
14.13.1 Patients Response to Checkpoint Inhibitor Therapies is Low in the Country
14.13.2 Canada Market Is Expected to Grow at a Steady Pase
14.13.3 Pre-COVID-19 Market Scenario
14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.14 Mexico Checkpoint Inhibitors Market Analysis
14.14.1 Mexico Is One of the Research Centres for Checkpoint Inhibitors.
14.14.2 PD-1/PD-L1 Inhibitors Continue to Change the Cancer Treatment Landscape in the Country
14.14.3 Pre-COVID-19 Market Scenario
14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 Europe Checkpoint Inhibitors Market Analysis
15.1 Europe Market Outlook
15.2 Europe Market Size Estimation and Forecast
15.2.1 Pre-COVID-19 Market Scenario
15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.3 Europe Market Size Estimation and Forecast by Region
15.3.1 Pre-COVID-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 Europe Market Size Estimation and Forecast by Category
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 Europe Market Size Estimation and Forecast by PD1 Inhibitors
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 Europe Market Size Estimation and Forecast by PD-L1 Inhibitors
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 Europe Market Size Estimation and Forecast by CTLA-4 Inhibitors:
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 Europe Market Size Estimation and Forecast by Cytokines Targets:
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 Europe Market Size Estimation and Forecast by Application
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 Europe Market Size Estimation and Forecast by Immuno Adjuvants:
15.10.1 Pre-COVID-19 Market Scenario
15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 Europe Market Size Estimation and Forecast by Immonumodulators
15.11.1 Pre-COVID-19 Market Scenario
15.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 Germany Checkpoint Inhibitors Market Analysis
15.12.1 German Companies Pursuing Bispecific for The Next Generation of Checkpoint Inhibitors
15.12.2 Companies Are Trying All Kinds of Combinations to Make Checkpoint Inhibitors Work for More People
15.12.3 Pre-COVID-19 Market Scenario
15.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 UK Checkpoint Inhibitors Market Analysis
15.13.1 High Tumour Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
15.13.2 UK Checkpoint Inhibitors Market to Grow at a Decent Rate
15.13.3 Pre-COVID-19 Market Scenario
15.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 France Checkpoint Inhibitors Market Analysis
15.14.1 Checkpoint Inhibitors Have Proven to Be Powerful Anti-Tumour Drugs
15.14.2 French Companies Facing Failures in Checkpoint Inhibitors Research
15.14.3 Pre-COVID-19 Market Scenario
15.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 Italy Checkpoint Inhibitors Market Analysis
15.15.1 Immunotherapy, And More Recently as Immuno-Oncology Therapies Are in Demand in The Country
15.15.2 Strong Pharmacovigilance Infrastructure in The Country.
15.15.3 Pre-COVID-19 Market Scenario
15.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.16 Spain Checkpoint Inhibitors Market Analysis
15.16.1 Prostate Cancer Is the Third Most Frequent Neoplasms in Spain
15.16.2 Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
15.16.3 Pre-COVID-19 Market Scenario
15.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.17 Rest of Europe Checkpoint Inhibitors Market Analysis
15.17.1 Pre-COVID-19 Market Scenario
15.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Asia-Pacific Checkpoint Inhibitors Market Analysis
16.1 Asia-Pacific Market Outlook
16.1.1 Chinese Checkpoint Inhibitors Are Poised to Change Global Market Dynamics
16.2 Asia-Pacific Market Size Estimation and Forecast
16.2.1 Pre-COVID-19 Market Scenario
16.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.3 Country Market Size Estimation and Forecast
16.3.1 Pre-COVID-19 Market Scenario
16.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.4 Asia-Pacific Market Breakdown by Category
16.4.1 Pre-COVID-19 Market Scenario
16.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.5 Asia-Pacific Market Breakdown by PD-1 Inhibitors
16.5.1 Pre-COVID-19 Market Scenario
16.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.6 Asia-Pacific Market Breakdown by PD-L1 Inhibitors
16.6.1 Pre-COVID-19 Market Scenario
16.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.7 Asia-Pacific Market Breakdown by CTLA-4 Inhibitors
16.7.1 Pre-COVID-19 Market Scenario
16.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.8 Asia-Pacific Market Breakdown by Cytokines Targets
16.8.1 Pre-COVID-19 Market Scenario
16.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.9 Asia-Pacific Market Breakdown by Application
16.9.1 Pre-COVID-19 Market Scenario
16.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.10 Asia-Pacific Market Breakdown by Immuno Adjuvants
16.10.1 Pre-COVID-19 Market Scenario
16.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.11 Asia-Pacific Market Breakdown by Immonumodulators
16.11.1 Pre-COVID-19 Market Scenario
16.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.12 China Checkpoint Inhibitors Market Analysis
16.12.1 China Supporting Local ICI Companies
16.12.2 International ICI Brands Seeking Market Access in China
16.12.3 Pre-COVID-19 Market Scenario
16.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.13 India Checkpoint Inhibitors Market Analysis
16.13.1 Increasing Breast Cancer Patients in India
16.13.2 Surgery Is the Mainstay of Treatment of the Early Stages of Breast Cancer in The Country
16.13.3 Upcoming Other Efficient Treatments such as Checkpoint Inhibitors in the Country
16.13.4 Pre-COVID-19 Market Scenario
16.13.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.14 Japan Checkpoint Inhibitors Market Analysis
16.14.1 Use of Neoadjuvant Trials to Drive Progress in Head and Neck Cancer Immunotherapy
16.14.2 Country is Focusing on Various Application Areas of Checkpoint Inhibitors
16.14.3 Pre-COVID-19 Market Scenario
16.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.15 South Korea Checkpoint Inhibitors Market Analysis
16.15.1 More Emphasis Given On Radiation & Immunotherapy as Compared to CHI
16.15.2 The Role of ICIs in Earlier Stages of Disease Is Unclear
16.15.3 Pre-COVID-19 Market Scenario
16.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.16 Australia Checkpoint Inhibitors Market Analysis
16.16.1 Australia Heading the Research on Checkpoint Inhibitors
16.16.2 Triebel spun out the Australian-European immunotherapy company
16.16.3 Pre-COVID-19 Market Scenario
16.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.17 Rest of Asia-Pacific Checkpoint Inhibitors Market Analysis
16.17.1 Pre-COVID-19 Market Scenario
16.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17 LAMEA Checkpoint Inhibitors Market Analysis
17.1 LAMEA Market Outlook
17.2 LAMEA Market Size Estimation and Forecast
17.2.1 Pre-COVID-19 Market Scenario
17.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.3 Country Market Size Estimation and Forecast
17.3.1 Pre-COVID-19 Market Scenario
17.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.4 LAMEA Market Breakdown by Category
17.4.1 Pre-COVID-19 Market Scenario
17.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.5 LAMEA Market Breakdown by PD-1 Inhibitors:
17.5.1 Pre-COVID-19 Market Scenario
17.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.6 LAMEA Market Breakdown by PD-L1 Inhibitors:
17.6.1 Pre-COVID-19 Market Scenario
17.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.7 LAMEA Market Breakdown by CTLA-4 Inhibitors:
17.7.1 Pre-COVID-19 Market Scenario
17.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.8 LAMEA Market Breakdown by Cytokines Targets:
17.8.1 Pre-COVID-19 Market Scenario
17.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.9 LAMEA Market Breakdown by Application:
17.9.1 Pre-COVID-19 Market Scenario
17.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.10 LAMEA Market Breakdown by Immuno Adjuvants:
17.10.1 Pre-COVID-19 Market Scenario
17.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.11 LAMEA Market Breakdown by Immunomodulators:
17.11.1 Pre-COVID-19 Market Scenario
17.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.12 Brazil Checkpoint Inhibitors Market Analysis
17.12.1 Country Adopting Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
17.12.2 Pre-COVID-19 Market Scenario
17.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.13 South Africa Checkpoint Inhibitors Market Analysis
17.13.1 Checkpoint Inhibitors Are Also Being Investigated in Combination with Chemotherapy
17.13.2 Pre-COVID-19 Market Scenario
17.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.14 Saudi Arabia Checkpoint Inhibitors Market Analysis
17.14.1 Increasing Importance of Immune Checkpoint Inhibitor Therapy
17.14.2 Pre-COVID-19 Market Scenario
17.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.15 Turkey Checkpoint Inhibitors Market Analysis
17.15.1 Immune Checkpoint Inhibitor Research Under Trials
17.15.2 Pre-COVID-19 Market Scenario
17.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.16 UAE Checkpoint Inhibitors Market Analysis
17.16.1 Negative Side of ICI Reported in UAE
17.16.2 Pre-COVID-19 Market Scenario
17.16.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.17 Rest of LAMEA Checkpoint Inhibitors Market Analysis
17.17.1 Pre-COVID-19 Market Scenario
17.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
18 Leading Company Profiles
18.1 Competitive Landscape
18.1.1 Collaborations and Partnerships in the Global Market
18.2 Seagen Inc.
18.2.1 Company Snapshot
18.2.2 Company Overview
18.2.3 Company Financial Profile
18.2.4 Company Product Benchmarking
18.2.5 Company Recent Developments
18.3 AGENUS INC.
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Company Financial Profile
18.3.4 Company Product Benchmarking
18.3.5 Company Recent Developments
18.4 Agilent Technologies
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Company Financial Profile
18.4.4 Company Product Benchmarking
18.4.5 Company Recent Developments
18.5 AbbVie Inc.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Company Financial Profile
18.5.4 Company Product Benchmarking
18.5.5 Company Recent Developments
18.6 xencor
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Company Financial Profile
18.6.4 Company Product Benchmarking
18.6.5 Company Recent Developments
18.7 Ono pharmaceutical
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Company Financial Profile
18.7.4 Company Product Benchmarking
18.7.5 Company Recent Developments
18.8 Sanofi SA
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Company Financial Profile
18.8.4 Company Product Benchmarking
18.8.5 Company Recent Developments
18.9 Eli Lilly and Co
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Company Financial Profile
18.9.4 Company Product Benchmarking
18.9.5 Company Recent Developments
18.10 Kyowa Hakko Kirin
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Company Financial Profile
18.10.4 Company Product Benchmarking
18.10.5 Company Recent Developments
18.11 Novartis
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Company Financial Profile
18.11.4 Company Product Benchmarking
18.11.5 Company Recent Developments
18.12 Pfizer Inc.
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Company Financial Profile
18.12.4 Company Product Benchmarking
18.12.5 Company Recent Developments
18.13 Roche
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Company Financial Profile
18.13.4 Company Product Benchmarking
18.13.5 Company Recent Developments
18.14 Merck & Co.
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Company Financial Profile
18.14.4 Company Product Benchmarking
18.14.5 Company Recent Developments
18.15 Incyte
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Company Financial Profile
18.15.4 Company Product Benchmarking
18.15.5 Company Recent Developments
18.16 Regeneron pharmaceuticals Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Company Financial Profile
18.16.4 Company Product Benchmarking
18.16.5 Company Recent Developments
18.17 Amgen Inc
18.17.1 Company Snapshot
18.17.2 Company Overview
18.17.3 Company Financial Profile
18.17.4 Company Product Benchmarking
18.17.5 Company Recent Developments
18.18 Bristol Myers Squibb
18.18.1 Company Snapshot
18.18.2 Company Overview
18.18.3 Company Financial Profile
18.18.4 Company Product Benchmarking
18.18.5 Company Recent Developments
18.19 Clovis Oncology
18.19.1 Company Snapshot
18.19.2 Company Overview
18.19.3 Company Financial Profile
18.19.4 Company Product Benchmarking
18.19.5 Company Recent Developments
18.20 Heptares Therapeutics Ltd.
18.20.1 Company Snapshot
18.20.2 Company Overview
18.20.3 Company Financial Profile
18.20.4 Company Product Benchmarking
18.20.5 Company Recent Developments
19 Conclusions & Recommendations Visiongain
19.1 Concluding Remarks from Visiongain
19.2 Recommendations for Market Players
19.3 North America to Dominate the Global Checkpoint Inhibitors Market
19.3.1 North America to Hold the Largest Share During Forecast Period
19.3.2 Asia-Pacific Region to Emerge as the Fastest Growing Market
20 Glossary Terms
List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Checkpoint Inhibitors Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
Table 3. Adverse Events Associated with Immune-Checkpoint Blockade
Table 4. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 10. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 14. Comparison of PD-L1-PD-L2 ligands
Table 15. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
Table 16. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications (continued)
Table 17. PD-1/PD-L1 Agents Pipeline Drugs
Table 18. Pembrolizumab Approved Indications
Table 19. Nivolumab Approved Indications
Table 20. Atezolizumab Approved Indications
Table 21. Regeneron’s NSCLC Development Program
Table 22. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 27. Avelumab Approved Indications
Table 28. Durvalumab Approved Indication
Table 29. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 34. CTLA-4 Agents in Pipeline
Table 35. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 36. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 41. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 51. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 54. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 56. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 57. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 58. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 59. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 62. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 63. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 64. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 67. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 68. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 69. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 73. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 74. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 78. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 79. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 88. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 89. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 93. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 94. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 98. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 99. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 103. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 104. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 113. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 114. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 118. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 119. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 123. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 124. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 128. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 129. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 134. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 144. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 154. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 159. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 179. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 184. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 189. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 194. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 199. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 204. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 209. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 289. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 290. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 291. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 292. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 293. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 294. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 295. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 296. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 297. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 298. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 299. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 300. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 301. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 302. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 303. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 304. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 305. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 306. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 307. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 308. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 309. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 310. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 311. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 312. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 313. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 314. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 315. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 316. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 317. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 318. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 319. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 320. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 321. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 322. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 323. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 324. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 325. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 326. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 327. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 328. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 329. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 330. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 331. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 332. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 333. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 334. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 335. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 336. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 337. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 338. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 339. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 340. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 341. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 342. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 343. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 344. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 345. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 346. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 347. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 348. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 349. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 350. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 351. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 352. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 353. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 354. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 355. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 356. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 357. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 358. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 359. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 360. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 361. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 362. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 363. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 364. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 365. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 366. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 367. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 368. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 369. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 370. Seagen Inc.: Company Information
Table 371. Seagen Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 372. Seagen Inc.: Company Product and Service Benchmarking
Table 373. Seagen Inc.: Company Recent Developments till Feb,2021
Table 374. AGENUS INC.: Company Information
Table 375. AGENUS INC.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 376. AGENUS INC.: Company Product and Service Benchmarking
Table 377. AGENUS INC.: Company Recent Developments till Feb,2021
Table 378. Agilent Technologies: Company Information
Table 379. Agilent Technologies: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 380. Agilent Technologies: Company Product and Service Benchmarking
Table 381. Agilent Technologies: Company Recent Developments till Feb,2021
Table 382. AbbVie Inc.: Company Information
Table 383. AbbVie Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 384. AbbVie Inc.: Company Product and Service Benchmarking
Table 385. AbbVie Inc.: Company Recent Developments till Feb,2021
Table 386. xencor: Company Information
Table 387. xencor : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 388. xencor : Company Product and Service Benchmarking
Table 389. xencor: Company Recent Developments till Feb,2021
Table 390. Ono pharmaceutical : Company Information
Table 391. Ono pharmaceutical : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 392. Ono pharmaceutical : Company Product and Service Benchmarking
Table 393. Ono pharmaceutical : Company Recent Developments till Feb,2021
Table 394. Sonafi: Company Information
Table 395. Sanofi: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 396. Sanofi: Company Product and Service Benchmarking
Table 397. Sanofi: Company Recent Developments till Feb,2021
Table 398. Eli Lilly And Co: Company Information
Table 399. Eli Lilly And Co: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 400. Eli Lilly And Co: Company Product and Service Benchmarking
Table 401. Eli Lilly And Co: Company Recent Developments till Feb,2021
Table 402. Kyowa Hakko Kirin : Company Information
Table 403. Kyowa Hakko Kirin : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 404. Kyowa Hakko Kirin : Company Product and Service Benchmarking
Table 405. Kyowa Hakko Kirin : Company Recent Developments till Feb,2021
Table 406. Novartis : Company Information
Table 407. Novartis : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 408. Novartis : Company Product and Service Benchmarking
Table 409. Novartis: Company Recent Developments till Feb,2021
Table 410. Pfizer Inc. : Company Information
Table 411. Pfizer Inc. : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 412. Pfizer Inc. : Company Product and Service Benchmarking
Table 413. Pfizer Inc. : Company Recent Developments till Feb,2021
Table 414. Roche: Company Information
Table 415. Roche: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 416. Roche: Company Product and Service Benchmarking
Table 417. Roche: Company Recent Developments till Feb,2021
Table 418. Merck & Co.: Company Information
Table 419. Merck & Co.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 420. Merck & Co. : Company Product and Service Benchmarking
Table 421. Merck & Co.: Company Recent Developments till Feb,2021
Table 422. Incyte : Company Information
Table 423. Incyte: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 424. Incyte : Company Product and Service Benchmarking
Table 425. Incyte: Company Recent Developments till Feb,2021
Table 426. Regeneron pharmaceuticals Inc.: Company Information
Table 427. Regeneron pharmaceuticals Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 428. Regeneron pharmaceuticals Inc.: Company Product and Service Benchmarking
Table 429. Regeneron pharmaceuticals Inc.: Company Recent Developments till Feb,2021
Table 430. Amgen Inc: Company Information
Table 431. Amgen Inc: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 432. Amgen Inc: Company Product and Service Benchmarking
Table 433. Amgen Inc: Company Recent Developments till Feb,2021
Table 434. Bristol Myers Squibb: Company Information
Table 435. Bristol Myers Squibb: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 436. Bristol Myers Squibb: Company Product and Service Benchmarking
Table 437. Bristol Myers Squibb: Company Recent Developments till Feb,2021
Table 438. Clovis Oncology: Company Information
Table 439. Clovis Oncology: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 440. Clovis Oncology: Company Product and Service Benchmarking
Table 441. Clovis Oncology: Company Recent Developments till Feb,2021
Table 442. Heptares Therapeutics Ltd.: Company Information
Table 443. Heptares Therapeutics Ltd.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 444. Heptares Therapeutics Ltd.: Company Product and Service Benchmarking
Table 445. Heptares Therapeutics Ltd.: Company Recent Developments till Feb,2021
Table 446. Abbreviations Used in Checkpoint Inhibitors
Table 447. Term Meaning
List of Figures
Figure 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 2. Global Checkpoint Inhibitors Market Segmentation
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Market: Market Trends
Figure 4. Potential Targets for checkpoint inhibition in clinical Evaluation
Figure 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 9. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Category, 2021, 2026, 2031 (%)
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by PD1 Inhibitors, 2021, 2026, 2031 (%)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 20. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by PDL1 Inhibitors, 2021, 2026, 2031 (%)
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 30. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 31. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 32. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 33. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Cytokines Targets, 2021, 2026, 2031 (%)
Figure 34. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 36. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 38. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 39. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Immuno Adjuvants, 2021, 2026, 2031 (%)
Figure 40. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 41. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 42. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 43. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 44. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 50. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application, 2021, 2026, 2031 (%)
Figure 51. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 52. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 53. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 54. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 56. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Region, 2021, 2026, 2031 (%)
Figure 57. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))
Figure 58. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 59. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 62. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 63. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 64. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 67. North America Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 68. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 69. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 73. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 74. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 78. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 79. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 88. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 89. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 93. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 94. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 98. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 99. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 103. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 104. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 113. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 114. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 118. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 119. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 123. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 124. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031(USD Mn, AGR (%))(V-Shape Recovery)
Figure 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 128. Europe Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 129. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 134. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
Figure 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 144. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 154. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 159. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 179. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 184. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 189. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 194. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 199. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 204. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 209. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
Figure 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 289. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 290. LAMEA Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 291. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 292. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 293. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 294. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 295. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 296. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 297. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 298. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 299. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 300. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
Figure 301. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 302. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 303. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 304. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 305. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 306. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 307. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 308. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 309. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 310. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 311. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 312. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 313. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 314. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 315. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 316. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 317. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 318. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 319. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 320. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 321. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 322. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 323. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 324. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 325. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 326. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 327. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 328. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 329. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 330. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 331. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 332. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 333. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 334. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 335. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 336. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 337. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 338. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 339. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 340. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 341. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 342. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 343. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 344. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 345. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 346. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 347. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 348. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 349. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 350. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 351. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 352. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 353. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 354. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 355. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 356. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 357. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 358. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 359. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 360. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 361. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 362. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 363. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 364. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 365. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 366. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 367. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 368. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 369. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 370. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 371. Global Checkpoint Inhibitors Market Share, 2020
Figure 372. Seagen Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 373. Seagen Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 374. Seagen Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 375. Seagen Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 376. AGENUS INC.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 377. AGENUS INC.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 378. AGENUS INC.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 379. AGENUS INC.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 380. Agilent Technologies: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 381. Agilent Technologies: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 382. Agilent Technologies: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 383. Agilent Technologies: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 384. AbbVie Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 385. AbbVie Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 386. AbbVie Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 387. AbbVie Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 388. xencor: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 389. xencor : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 390. xencor : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 391. xencor : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 392. Ono pharmaceutical : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 393. Ono pharmaceutical : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 394. Ono pharmaceutical: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 395. Ono pharmaceutical : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 396. Sanofi: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 397. Sanofi: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 398. Sanofi: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 399. Sanofi: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 400. Eli Lilly And Co: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 401. Eli Lilly And Co: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 402. Eli Lilly And Co: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 403. Eli Lilly And Co: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 404. Kyowa Hakko Kirin : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 405. Kyowa Hakko Kirin : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 406. Kyowa Hakko Kirin : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 407. Kyowa Hakko Kirin : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 408. Novartis: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 409. Novartis : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 410. Novartis : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 411. Novartis : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 412. Pfizer Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 413. Pfizer Inc. : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 414. Pfizer Inc. : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 415. Pfizer Inc. : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 416. Roche: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 417. Roche: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 418. Roche: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 419. Roche: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 420. Merck & Co. : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 421. Merck & Co. : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 422. Merck & Co. : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 423. Merck & Co. : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 424. Incyte: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 425. Incyte : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 426. Incyte: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 427. Incyte: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 428. Regeneron pharmaceuticals Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 429. Regeneron pharmaceuticals Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 430. Regeneron pharmaceuticals Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 431. Regeneron pharmaceuticals Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 432. Amgen Inc: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 433. Amgen Inc: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 434. Amgen Inc: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 435. Amgen Inc: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 436. Bristol Myers Squibb: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 437. Bristol Myers Squibb: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 438. Bristol Myers Squibb: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 439. Bristol Myers Squibb: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 440. Clovis Oncology: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 441. Clovis Oncology: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 442. Clovis Oncology: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 443. Clovis Oncology: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 444. Heptares Therapeutics Ltd.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 445. Heptares Therapeutics Ltd.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 446. Heptares Therapeutics Ltd.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 447. Heptares Therapeutics Ltd.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 448. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Region, 2021, 2026, 2031 (%)
1.1 Introduction to Checkpoint Inhibitors Market
1.2 Global Checkpoint Inhibitors Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Checkpoint Inhibitors Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered by This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Visiongain Reports
1.13 About Visiongain
2 Executive Summary
3 Checkpoint Inhibitors Industry Structure
3.1 Overview
3.1.1 Inhibitory Immune Checkpoint Targets
3.1.2 Immunometabolic Modulatory Targets
3.1.3 CAR-T Cells
4 Global Market Dynamics
4.1 Current Trends in the Global Market
4.2 Market Driving Factors
4.2.1 Peripheral Immune Responses Are Critical in Achieving Favourable Clinical Outcomes
4.2.2 New Products/Therapy Launch Are Gaining Tractions in the Global Market
4.2.3 Increasing Support from FDA in the Approval Procedures
4.3 Market Restraining Factors
4.3.1 Most Patients and Cancers Do Not Respond to Checkpoint Inhibitor Therapies
4.3.2 Immune-Related Adverse Events Occurred, Restraining Further Research
4.3.3 An Increased Risk of Thromboembolism
4.4 Opportunities in the Global Market
4.4.1 Unprecedented Advances in Cancer Immunotherapy
4.4.2 Unmet Medical Needs
4.4.3 New Combinations Therapies Creating New Opportunities
4.5 Challenges in the Global Market
4.5.1 Lack of Understanding in Regards to Checkpoint Inhibitors Mechanisms
4.5.2 Resistance to Immune Checkpoint Inhibitors
4.5.3 Whether irAE Presentation Correlates with ICI efficacy is a Challenge
5 Global Checkpoint Inhibitors Market Analysis
5.1 Global Market Outlook
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario
5.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Market Breakdown by Category
6.1 Segment Overview
6.1.1 PD-1 inhibitor:
6.1.2 PD-L1 Inhibitors:
6.1.3 CTLA-4 Inhibitors:
6.1.4 Cytokines Targets:
6.1.5 Immuno Adjuvants
6.1.6 Immunomodulators
6.1.7 Pre-COVID-19 Market Scenario
6.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Market Breakdown by PD1 Inhibitors
7.1 Segment Overview
7.1.1 Introduction to PD-1/PD-L1 Agents
7.1.2 Pembrolizumab (Keytruda), Merck & Co.
7.1.3 Nivolumab (Opdivo), BMS
7.1.4 Atezolizumab (Tecentriq), Genentech
7.1.5 Cemiplimab (Libtayo), Regeneron/Sanofi
7.1.6 Pre-COVID-19 Market Scenario
7.1.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7.2 Global Market Breakdown by PD-L1 Inhibitors
7.2.1 Avelumab (Bavencio), Merck KGaA/Pfizer
7.2.2 Durvalumab (Imfinzi), AstraZeneca
7.2.3 Pre-COVID-19 Market Scenario
7.2.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Market Breakdown by CTLA-4 Inhibitors
8.1 Segment Overview
8.1.1 Pre-COVID-19 Market Scenario
8.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Market Breakdown by Cytokines Target
9.1 Segment Overview
9.1.1 Pre-COVID-19 Market Scenario
9.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Market Breakdown by Immuno Adjuvants
10.1 Segment Overview
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Market Breakdown by Immuno Modulators
11.1 Segment Overview
11.2 Pre-COVID-19 Market Scenario
11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 Global Market Breakdown by Application
12.1 Segment Overview
12.1.1 Lung Cancer Treatment
12.1.2 Renal Cancer Treatment
12.1.3 Blood Cancer Treatment
12.1.4 Bladder Cancer Treatment
12.2 Pre-COVID-19 Market Scenario
12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Global Checkpoint Inhibitors Market by Region
13.1 Regional Market Size Estimation and Forecast
13.1.1 Pre-COVID-19 Market Scenario
13.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 North America Checkpoint Inhibitors Market Analysis
14.1 North America Market Outlook
14.2 North America Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Country Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 North America Market Breakdown by Category
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 North America Market Breakdown by PD-1 Inhibitors
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 North America Market Breakdown by PD-L1 Inhibitors
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 North America Market Breakdown by CTLA-4 Inhibitors
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 North America Market Breakdown by Cytokines Target
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 North America Market Breakdown by Application
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 North America Market Breakdown by Immuno Adjuvants
14.10.1 Pre-COVID-19 Market Scenario
14.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 North America Market Breakdown by Immunomodulators
14.11.1 Pre-COVID-19 Market Scenario
14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 US Checkpoint Inhibitors Market Analysis
14.12.1 Clinical Use of Checkpoint Inhibitors is Growing Rapidly in the US
14.12.2 Acceptance of Checkpoint Inhibitors for Treating Cancer
14.12.3 Pre-COVID-19 Market Scenario
14.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 Canada Checkpoint Inhibitors Market Analysis
14.13.1 Patients Response to Checkpoint Inhibitor Therapies is Low in the Country
14.13.2 Canada Market Is Expected to Grow at a Steady Pase
14.13.3 Pre-COVID-19 Market Scenario
14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.14 Mexico Checkpoint Inhibitors Market Analysis
14.14.1 Mexico Is One of the Research Centres for Checkpoint Inhibitors.
14.14.2 PD-1/PD-L1 Inhibitors Continue to Change the Cancer Treatment Landscape in the Country
14.14.3 Pre-COVID-19 Market Scenario
14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 Europe Checkpoint Inhibitors Market Analysis
15.1 Europe Market Outlook
15.2 Europe Market Size Estimation and Forecast
15.2.1 Pre-COVID-19 Market Scenario
15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.3 Europe Market Size Estimation and Forecast by Region
15.3.1 Pre-COVID-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 Europe Market Size Estimation and Forecast by Category
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 Europe Market Size Estimation and Forecast by PD1 Inhibitors
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 Europe Market Size Estimation and Forecast by PD-L1 Inhibitors
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 Europe Market Size Estimation and Forecast by CTLA-4 Inhibitors:
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 Europe Market Size Estimation and Forecast by Cytokines Targets:
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 Europe Market Size Estimation and Forecast by Application
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 Europe Market Size Estimation and Forecast by Immuno Adjuvants:
15.10.1 Pre-COVID-19 Market Scenario
15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 Europe Market Size Estimation and Forecast by Immonumodulators
15.11.1 Pre-COVID-19 Market Scenario
15.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 Germany Checkpoint Inhibitors Market Analysis
15.12.1 German Companies Pursuing Bispecific for The Next Generation of Checkpoint Inhibitors
15.12.2 Companies Are Trying All Kinds of Combinations to Make Checkpoint Inhibitors Work for More People
15.12.3 Pre-COVID-19 Market Scenario
15.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 UK Checkpoint Inhibitors Market Analysis
15.13.1 High Tumour Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
15.13.2 UK Checkpoint Inhibitors Market to Grow at a Decent Rate
15.13.3 Pre-COVID-19 Market Scenario
15.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 France Checkpoint Inhibitors Market Analysis
15.14.1 Checkpoint Inhibitors Have Proven to Be Powerful Anti-Tumour Drugs
15.14.2 French Companies Facing Failures in Checkpoint Inhibitors Research
15.14.3 Pre-COVID-19 Market Scenario
15.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 Italy Checkpoint Inhibitors Market Analysis
15.15.1 Immunotherapy, And More Recently as Immuno-Oncology Therapies Are in Demand in The Country
15.15.2 Strong Pharmacovigilance Infrastructure in The Country.
15.15.3 Pre-COVID-19 Market Scenario
15.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.16 Spain Checkpoint Inhibitors Market Analysis
15.16.1 Prostate Cancer Is the Third Most Frequent Neoplasms in Spain
15.16.2 Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
15.16.3 Pre-COVID-19 Market Scenario
15.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.17 Rest of Europe Checkpoint Inhibitors Market Analysis
15.17.1 Pre-COVID-19 Market Scenario
15.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Asia-Pacific Checkpoint Inhibitors Market Analysis
16.1 Asia-Pacific Market Outlook
16.1.1 Chinese Checkpoint Inhibitors Are Poised to Change Global Market Dynamics
16.2 Asia-Pacific Market Size Estimation and Forecast
16.2.1 Pre-COVID-19 Market Scenario
16.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.3 Country Market Size Estimation and Forecast
16.3.1 Pre-COVID-19 Market Scenario
16.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.4 Asia-Pacific Market Breakdown by Category
16.4.1 Pre-COVID-19 Market Scenario
16.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.5 Asia-Pacific Market Breakdown by PD-1 Inhibitors
16.5.1 Pre-COVID-19 Market Scenario
16.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.6 Asia-Pacific Market Breakdown by PD-L1 Inhibitors
16.6.1 Pre-COVID-19 Market Scenario
16.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.7 Asia-Pacific Market Breakdown by CTLA-4 Inhibitors
16.7.1 Pre-COVID-19 Market Scenario
16.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.8 Asia-Pacific Market Breakdown by Cytokines Targets
16.8.1 Pre-COVID-19 Market Scenario
16.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.9 Asia-Pacific Market Breakdown by Application
16.9.1 Pre-COVID-19 Market Scenario
16.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.10 Asia-Pacific Market Breakdown by Immuno Adjuvants
16.10.1 Pre-COVID-19 Market Scenario
16.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.11 Asia-Pacific Market Breakdown by Immonumodulators
16.11.1 Pre-COVID-19 Market Scenario
16.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.12 China Checkpoint Inhibitors Market Analysis
16.12.1 China Supporting Local ICI Companies
16.12.2 International ICI Brands Seeking Market Access in China
16.12.3 Pre-COVID-19 Market Scenario
16.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.13 India Checkpoint Inhibitors Market Analysis
16.13.1 Increasing Breast Cancer Patients in India
16.13.2 Surgery Is the Mainstay of Treatment of the Early Stages of Breast Cancer in The Country
16.13.3 Upcoming Other Efficient Treatments such as Checkpoint Inhibitors in the Country
16.13.4 Pre-COVID-19 Market Scenario
16.13.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.14 Japan Checkpoint Inhibitors Market Analysis
16.14.1 Use of Neoadjuvant Trials to Drive Progress in Head and Neck Cancer Immunotherapy
16.14.2 Country is Focusing on Various Application Areas of Checkpoint Inhibitors
16.14.3 Pre-COVID-19 Market Scenario
16.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.15 South Korea Checkpoint Inhibitors Market Analysis
16.15.1 More Emphasis Given On Radiation & Immunotherapy as Compared to CHI
16.15.2 The Role of ICIs in Earlier Stages of Disease Is Unclear
16.15.3 Pre-COVID-19 Market Scenario
16.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.16 Australia Checkpoint Inhibitors Market Analysis
16.16.1 Australia Heading the Research on Checkpoint Inhibitors
16.16.2 Triebel spun out the Australian-European immunotherapy company
16.16.3 Pre-COVID-19 Market Scenario
16.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.17 Rest of Asia-Pacific Checkpoint Inhibitors Market Analysis
16.17.1 Pre-COVID-19 Market Scenario
16.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17 LAMEA Checkpoint Inhibitors Market Analysis
17.1 LAMEA Market Outlook
17.2 LAMEA Market Size Estimation and Forecast
17.2.1 Pre-COVID-19 Market Scenario
17.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.3 Country Market Size Estimation and Forecast
17.3.1 Pre-COVID-19 Market Scenario
17.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.4 LAMEA Market Breakdown by Category
17.4.1 Pre-COVID-19 Market Scenario
17.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.5 LAMEA Market Breakdown by PD-1 Inhibitors:
17.5.1 Pre-COVID-19 Market Scenario
17.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.6 LAMEA Market Breakdown by PD-L1 Inhibitors:
17.6.1 Pre-COVID-19 Market Scenario
17.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.7 LAMEA Market Breakdown by CTLA-4 Inhibitors:
17.7.1 Pre-COVID-19 Market Scenario
17.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.8 LAMEA Market Breakdown by Cytokines Targets:
17.8.1 Pre-COVID-19 Market Scenario
17.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.9 LAMEA Market Breakdown by Application:
17.9.1 Pre-COVID-19 Market Scenario
17.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.10 LAMEA Market Breakdown by Immuno Adjuvants:
17.10.1 Pre-COVID-19 Market Scenario
17.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.11 LAMEA Market Breakdown by Immunomodulators:
17.11.1 Pre-COVID-19 Market Scenario
17.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.12 Brazil Checkpoint Inhibitors Market Analysis
17.12.1 Country Adopting Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
17.12.2 Pre-COVID-19 Market Scenario
17.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.13 South Africa Checkpoint Inhibitors Market Analysis
17.13.1 Checkpoint Inhibitors Are Also Being Investigated in Combination with Chemotherapy
17.13.2 Pre-COVID-19 Market Scenario
17.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.14 Saudi Arabia Checkpoint Inhibitors Market Analysis
17.14.1 Increasing Importance of Immune Checkpoint Inhibitor Therapy
17.14.2 Pre-COVID-19 Market Scenario
17.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.15 Turkey Checkpoint Inhibitors Market Analysis
17.15.1 Immune Checkpoint Inhibitor Research Under Trials
17.15.2 Pre-COVID-19 Market Scenario
17.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.16 UAE Checkpoint Inhibitors Market Analysis
17.16.1 Negative Side of ICI Reported in UAE
17.16.2 Pre-COVID-19 Market Scenario
17.16.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.17 Rest of LAMEA Checkpoint Inhibitors Market Analysis
17.17.1 Pre-COVID-19 Market Scenario
17.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
18 Leading Company Profiles
18.1 Competitive Landscape
18.1.1 Collaborations and Partnerships in the Global Market
18.2 Seagen Inc.
18.2.1 Company Snapshot
18.2.2 Company Overview
18.2.3 Company Financial Profile
18.2.4 Company Product Benchmarking
18.2.5 Company Recent Developments
18.3 AGENUS INC.
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Company Financial Profile
18.3.4 Company Product Benchmarking
18.3.5 Company Recent Developments
18.4 Agilent Technologies
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Company Financial Profile
18.4.4 Company Product Benchmarking
18.4.5 Company Recent Developments
18.5 AbbVie Inc.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Company Financial Profile
18.5.4 Company Product Benchmarking
18.5.5 Company Recent Developments
18.6 xencor
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Company Financial Profile
18.6.4 Company Product Benchmarking
18.6.5 Company Recent Developments
18.7 Ono pharmaceutical
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Company Financial Profile
18.7.4 Company Product Benchmarking
18.7.5 Company Recent Developments
18.8 Sanofi SA
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Company Financial Profile
18.8.4 Company Product Benchmarking
18.8.5 Company Recent Developments
18.9 Eli Lilly and Co
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Company Financial Profile
18.9.4 Company Product Benchmarking
18.9.5 Company Recent Developments
18.10 Kyowa Hakko Kirin
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Company Financial Profile
18.10.4 Company Product Benchmarking
18.10.5 Company Recent Developments
18.11 Novartis
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Company Financial Profile
18.11.4 Company Product Benchmarking
18.11.5 Company Recent Developments
18.12 Pfizer Inc.
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Company Financial Profile
18.12.4 Company Product Benchmarking
18.12.5 Company Recent Developments
18.13 Roche
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Company Financial Profile
18.13.4 Company Product Benchmarking
18.13.5 Company Recent Developments
18.14 Merck & Co.
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Company Financial Profile
18.14.4 Company Product Benchmarking
18.14.5 Company Recent Developments
18.15 Incyte
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Company Financial Profile
18.15.4 Company Product Benchmarking
18.15.5 Company Recent Developments
18.16 Regeneron pharmaceuticals Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Company Financial Profile
18.16.4 Company Product Benchmarking
18.16.5 Company Recent Developments
18.17 Amgen Inc
18.17.1 Company Snapshot
18.17.2 Company Overview
18.17.3 Company Financial Profile
18.17.4 Company Product Benchmarking
18.17.5 Company Recent Developments
18.18 Bristol Myers Squibb
18.18.1 Company Snapshot
18.18.2 Company Overview
18.18.3 Company Financial Profile
18.18.4 Company Product Benchmarking
18.18.5 Company Recent Developments
18.19 Clovis Oncology
18.19.1 Company Snapshot
18.19.2 Company Overview
18.19.3 Company Financial Profile
18.19.4 Company Product Benchmarking
18.19.5 Company Recent Developments
18.20 Heptares Therapeutics Ltd.
18.20.1 Company Snapshot
18.20.2 Company Overview
18.20.3 Company Financial Profile
18.20.4 Company Product Benchmarking
18.20.5 Company Recent Developments
19 Conclusions & Recommendations Visiongain
19.1 Concluding Remarks from Visiongain
19.2 Recommendations for Market Players
19.3 North America to Dominate the Global Checkpoint Inhibitors Market
19.3.1 North America to Hold the Largest Share During Forecast Period
19.3.2 Asia-Pacific Region to Emerge as the Fastest Growing Market
20 Glossary Terms
List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Checkpoint Inhibitors Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
Table 3. Adverse Events Associated with Immune-Checkpoint Blockade
Table 4. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 10. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 14. Comparison of PD-L1-PD-L2 ligands
Table 15. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
Table 16. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications (continued)
Table 17. PD-1/PD-L1 Agents Pipeline Drugs
Table 18. Pembrolizumab Approved Indications
Table 19. Nivolumab Approved Indications
Table 20. Atezolizumab Approved Indications
Table 21. Regeneron’s NSCLC Development Program
Table 22. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 27. Avelumab Approved Indications
Table 28. Durvalumab Approved Indication
Table 29. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 34. CTLA-4 Agents in Pipeline
Table 35. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 36. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 41. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 51. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 54. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 56. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 57. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 58. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 59. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 62. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 63. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 64. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 67. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 68. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 69. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 73. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 74. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 78. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 79. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 88. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 89. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 93. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 94. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 98. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 99. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 103. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 104. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 113. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 114. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 118. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 119. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 123. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 124. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 128. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 129. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 134. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 144. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 154. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 159. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 179. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 184. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 189. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 194. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 199. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 204. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 209. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 289. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 290. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 291. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 292. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 293. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 294. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 295. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 296. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 297. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 298. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 299. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 300. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 301. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 302. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 303. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 304. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 305. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 306. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 307. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 308. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 309. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 310. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 311. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 312. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 313. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 314. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 315. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 316. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 317. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 318. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 319. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 320. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 321. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 322. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 323. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 324. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 325. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 326. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 327. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 328. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 329. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 330. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 331. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 332. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 333. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 334. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 335. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 336. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 337. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 338. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 339. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 340. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 341. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 342. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 343. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 344. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 345. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 346. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 347. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 348. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 349. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 350. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 351. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 352. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 353. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 354. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 355. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 356. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 357. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 358. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 359. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 360. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 361. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 362. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 363. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 364. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 365. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 366. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 367. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 368. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 369. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 370. Seagen Inc.: Company Information
Table 371. Seagen Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 372. Seagen Inc.: Company Product and Service Benchmarking
Table 373. Seagen Inc.: Company Recent Developments till Feb,2021
Table 374. AGENUS INC.: Company Information
Table 375. AGENUS INC.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 376. AGENUS INC.: Company Product and Service Benchmarking
Table 377. AGENUS INC.: Company Recent Developments till Feb,2021
Table 378. Agilent Technologies: Company Information
Table 379. Agilent Technologies: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 380. Agilent Technologies: Company Product and Service Benchmarking
Table 381. Agilent Technologies: Company Recent Developments till Feb,2021
Table 382. AbbVie Inc.: Company Information
Table 383. AbbVie Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 384. AbbVie Inc.: Company Product and Service Benchmarking
Table 385. AbbVie Inc.: Company Recent Developments till Feb,2021
Table 386. xencor: Company Information
Table 387. xencor : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 388. xencor : Company Product and Service Benchmarking
Table 389. xencor: Company Recent Developments till Feb,2021
Table 390. Ono pharmaceutical : Company Information
Table 391. Ono pharmaceutical : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 392. Ono pharmaceutical : Company Product and Service Benchmarking
Table 393. Ono pharmaceutical : Company Recent Developments till Feb,2021
Table 394. Sonafi: Company Information
Table 395. Sanofi: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 396. Sanofi: Company Product and Service Benchmarking
Table 397. Sanofi: Company Recent Developments till Feb,2021
Table 398. Eli Lilly And Co: Company Information
Table 399. Eli Lilly And Co: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 400. Eli Lilly And Co: Company Product and Service Benchmarking
Table 401. Eli Lilly And Co: Company Recent Developments till Feb,2021
Table 402. Kyowa Hakko Kirin : Company Information
Table 403. Kyowa Hakko Kirin : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 404. Kyowa Hakko Kirin : Company Product and Service Benchmarking
Table 405. Kyowa Hakko Kirin : Company Recent Developments till Feb,2021
Table 406. Novartis : Company Information
Table 407. Novartis : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 408. Novartis : Company Product and Service Benchmarking
Table 409. Novartis: Company Recent Developments till Feb,2021
Table 410. Pfizer Inc. : Company Information
Table 411. Pfizer Inc. : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 412. Pfizer Inc. : Company Product and Service Benchmarking
Table 413. Pfizer Inc. : Company Recent Developments till Feb,2021
Table 414. Roche: Company Information
Table 415. Roche: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 416. Roche: Company Product and Service Benchmarking
Table 417. Roche: Company Recent Developments till Feb,2021
Table 418. Merck & Co.: Company Information
Table 419. Merck & Co.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 420. Merck & Co. : Company Product and Service Benchmarking
Table 421. Merck & Co.: Company Recent Developments till Feb,2021
Table 422. Incyte : Company Information
Table 423. Incyte: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 424. Incyte : Company Product and Service Benchmarking
Table 425. Incyte: Company Recent Developments till Feb,2021
Table 426. Regeneron pharmaceuticals Inc.: Company Information
Table 427. Regeneron pharmaceuticals Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 428. Regeneron pharmaceuticals Inc.: Company Product and Service Benchmarking
Table 429. Regeneron pharmaceuticals Inc.: Company Recent Developments till Feb,2021
Table 430. Amgen Inc: Company Information
Table 431. Amgen Inc: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 432. Amgen Inc: Company Product and Service Benchmarking
Table 433. Amgen Inc: Company Recent Developments till Feb,2021
Table 434. Bristol Myers Squibb: Company Information
Table 435. Bristol Myers Squibb: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 436. Bristol Myers Squibb: Company Product and Service Benchmarking
Table 437. Bristol Myers Squibb: Company Recent Developments till Feb,2021
Table 438. Clovis Oncology: Company Information
Table 439. Clovis Oncology: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 440. Clovis Oncology: Company Product and Service Benchmarking
Table 441. Clovis Oncology: Company Recent Developments till Feb,2021
Table 442. Heptares Therapeutics Ltd.: Company Information
Table 443. Heptares Therapeutics Ltd.: Company Revenue 2016-2020 (US$Mn, AGR %)
Table 444. Heptares Therapeutics Ltd.: Company Product and Service Benchmarking
Table 445. Heptares Therapeutics Ltd.: Company Recent Developments till Feb,2021
Table 446. Abbreviations Used in Checkpoint Inhibitors
Table 447. Term Meaning
List of Figures
Figure 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 2. Global Checkpoint Inhibitors Market Segmentation
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Market: Market Trends
Figure 4. Potential Targets for checkpoint inhibition in clinical Evaluation
Figure 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 9. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Category, 2021, 2026, 2031 (%)
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by PD1 Inhibitors, 2021, 2026, 2031 (%)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 20. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by PDL1 Inhibitors, 2021, 2026, 2031 (%)
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 30. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 31. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 32. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 33. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Cytokines Targets, 2021, 2026, 2031 (%)
Figure 34. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 36. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 38. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 39. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Immuno Adjuvants, 2021, 2026, 2031 (%)
Figure 40. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 41. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 42. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 43. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 44. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 50. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application, 2021, 2026, 2031 (%)
Figure 51. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 52. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 53. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 54. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 56. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Region, 2021, 2026, 2031 (%)
Figure 57. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))
Figure 58. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 59. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 62. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 63. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 64. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 67. North America Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 68. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 69. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 73. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 74. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 78. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 79. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 88. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 89. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 93. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 94. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 98. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 99. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 103. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 104. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 113. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 114. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 118. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 119. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 123. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 124. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031(USD Mn, AGR (%))(V-Shape Recovery)
Figure 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 128. Europe Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 129. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 134. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
Figure 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 144. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 154. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 159. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 179. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 184. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 189. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 194. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 199. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 204. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 209. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
Figure 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 289. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 290. LAMEA Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
Figure 291. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
Figure 292. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 293. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 294. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 295. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 296. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
Figure 297. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
Figure 298. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
Figure 299. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
Figure 300. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
Figure 301. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
Figure 302. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 303. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 304. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 305. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 306. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 307. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 308. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 309. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 310. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 311. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 312. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 313. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 314. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 315. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 316. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
Figure 317. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 318. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 319. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 320. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 321. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
Figure 322. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 323. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 324. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 325. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 326. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
Figure 327. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 328. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 329. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 330. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 331. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
Figure 332. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 333. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 334. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 335. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 336. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
Figure 337. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 338. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 339. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 340. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 341. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 342. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 343. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 344. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 345. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 346. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 347. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 348. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 349. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 350. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 351. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 352. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 353. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 354. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 355. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 356. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 357. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 358. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 359. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 360. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 361. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 362. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 363. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 364. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 365. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 366. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
Figure 367. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
Figure 368. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
Figure 369. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
Figure 370. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
Figure 371. Global Checkpoint Inhibitors Market Share, 2020
Figure 372. Seagen Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 373. Seagen Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 374. Seagen Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 375. Seagen Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 376. AGENUS INC.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 377. AGENUS INC.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 378. AGENUS INC.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 379. AGENUS INC.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 380. Agilent Technologies: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 381. Agilent Technologies: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 382. Agilent Technologies: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 383. Agilent Technologies: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 384. AbbVie Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 385. AbbVie Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 386. AbbVie Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 387. AbbVie Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 388. xencor: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 389. xencor : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 390. xencor : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 391. xencor : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 392. Ono pharmaceutical : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 393. Ono pharmaceutical : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 394. Ono pharmaceutical: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 395. Ono pharmaceutical : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 396. Sanofi: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 397. Sanofi: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 398. Sanofi: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 399. Sanofi: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 400. Eli Lilly And Co: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 401. Eli Lilly And Co: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 402. Eli Lilly And Co: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 403. Eli Lilly And Co: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 404. Kyowa Hakko Kirin : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 405. Kyowa Hakko Kirin : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 406. Kyowa Hakko Kirin : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 407. Kyowa Hakko Kirin : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 408. Novartis: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 409. Novartis : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 410. Novartis : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 411. Novartis : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 412. Pfizer Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 413. Pfizer Inc. : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 414. Pfizer Inc. : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 415. Pfizer Inc. : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 416. Roche: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 417. Roche: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 418. Roche: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 419. Roche: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 420. Merck & Co. : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 421. Merck & Co. : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 422. Merck & Co. : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 423. Merck & Co. : Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 424. Incyte: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 425. Incyte : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 426. Incyte: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 427. Incyte: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 428. Regeneron pharmaceuticals Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 429. Regeneron pharmaceuticals Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 430. Regeneron pharmaceuticals Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 431. Regeneron pharmaceuticals Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 432. Amgen Inc: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 433. Amgen Inc: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 434. Amgen Inc: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 435. Amgen Inc: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 436. Bristol Myers Squibb: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 437. Bristol Myers Squibb: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 438. Bristol Myers Squibb: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 439. Bristol Myers Squibb: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 440. Clovis Oncology: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 441. Clovis Oncology: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 442. Clovis Oncology: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 443. Clovis Oncology: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 444. Heptares Therapeutics Ltd.: Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 445. Heptares Therapeutics Ltd.: Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 446. Heptares Therapeutics Ltd.: Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 447. Heptares Therapeutics Ltd.: Company EBITDA2016-2020 (US$Mn, AGR %)
Figure 448. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Region, 2021, 2026, 2031 (%)
List of Companies Profiled in the report
Seagen Inc.,
Agenus Inc. (Agenus)
Agilent Technologies, Inc.
AbbVie Inc. (AbbVie)
Amgen Inc.
Bristol-Myers Squibb Company
Clovis Oncology, Inc.
Eli Lilly and Company
Heptares Therapeutics Ltd.
Incyte Corporation
Merck & Co., Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc. (Pfizer)
Regeneron Pharmaceuticals, Inc.
Roche Holding AG (Roche)
Sanofi SA
Xencor, Inc.
List of Other Companies Mentioned in the report
AbbVie
Abramson Cancer Center
Admune Therapeutics
Aduro Biotech
Advaxis, Inc.
Agenus Inc.
Agilent Technologies
Alcon
Amgen
Amplimmune
AnaptysBio
Apexigen, Inc.
AREVA Med
ARIAD Pharmaceuticals, Inc.
Array BioPharma
AstraZeneca
Aurigene Discovery Technologies
Basilea Pharmaceutica Ltd.
BeiGene
Bristol-Myers Squibb
Calithera Biosciences Inc.
cCAM Biotherapeutics
Celgene
Celldex Therapeutics Inc.
Chugai
Clal Biotech
Clovis Oncology, Inc.
CoStim Pharmaceuticals
CureTech, Ltd.
Curis, Inc.
Daiichi Sankyo Company, Limited
Dako
DNAtrix
Dynavax
Eddingpharm
Eisai Co., Ltd.
Eli Lilly
Exelixis, Inc.
GE Healthcare
GeneCentric Diagnostics, Inc.
Heptares Therapeutics
IBM
Immune Design
Immunocore Limited
Immutep
Incyte
Innate Pharma
Inovio Pharmaceuticals
IOmet Pharma Ltd.
Janssen Biotech, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin
MacroGenicS Inc.
Medarex
MedImmune
Medivation, Inc
Merck & Co.
Merus N.V.
Moderna Therapeutics
Moffitt Cancer Center
MS
NanoString Technologies, Inc.
NEC Corporation
NewLink Genetics
Novartis
Oncothyreon Inc.
Ono Pharmaceutical
Peregrine Pharmaceuticals
Pfizer, Inc.
Plexxikon Inc.
Prima Biomed
Regeneron Pharmaceuticals
Roche
Sandoz
Sanofi
Seattle Genetics, Inc.
Sosei Group Corporation
Surface Oncology
Syndax Pharmaceuticals
Syros Pharmaceuticals, Inc.
TARIS Biomedical LLC
TESARO, Inc.
TetraLogic Pharmaceuticals Corporation
Transgene SA
Western Oncolytics
Xencor
List of Associations Mentioned in the Report
Cancer Research Institute
Central Social Insurance Medical Council
Data Monitoring Committee
Early Access to Medicines Scheme
European Cancer Congress
European Medicines Agency
European Organisation for Research and Treatment of Cancer
MD Anderson Cancer Center
Medicines and Healthcare Products Regulatory Agency
Ministry of Health, Labour, and Welfare
National Cancer Institute
National Institute for Health and Clinical Excellence
QIMR Berghofer Medical Research Institute
University of Pittsburgh
Yamaguchi University
Seagen Inc.,
Agenus Inc. (Agenus)
Agilent Technologies, Inc.
AbbVie Inc. (AbbVie)
Amgen Inc.
Bristol-Myers Squibb Company
Clovis Oncology, Inc.
Eli Lilly and Company
Heptares Therapeutics Ltd.
Incyte Corporation
Merck & Co., Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc. (Pfizer)
Regeneron Pharmaceuticals, Inc.
Roche Holding AG (Roche)
Sanofi SA
Xencor, Inc.
List of Other Companies Mentioned in the report
AbbVie
Abramson Cancer Center
Admune Therapeutics
Aduro Biotech
Advaxis, Inc.
Agenus Inc.
Agilent Technologies
Alcon
Amgen
Amplimmune
AnaptysBio
Apexigen, Inc.
AREVA Med
ARIAD Pharmaceuticals, Inc.
Array BioPharma
AstraZeneca
Aurigene Discovery Technologies
Basilea Pharmaceutica Ltd.
BeiGene
Bristol-Myers Squibb
Calithera Biosciences Inc.
cCAM Biotherapeutics
Celgene
Celldex Therapeutics Inc.
Chugai
Clal Biotech
Clovis Oncology, Inc.
CoStim Pharmaceuticals
CureTech, Ltd.
Curis, Inc.
Daiichi Sankyo Company, Limited
Dako
DNAtrix
Dynavax
Eddingpharm
Eisai Co., Ltd.
Eli Lilly
Exelixis, Inc.
GE Healthcare
GeneCentric Diagnostics, Inc.
Heptares Therapeutics
IBM
Immune Design
Immunocore Limited
Immutep
Incyte
Innate Pharma
Inovio Pharmaceuticals
IOmet Pharma Ltd.
Janssen Biotech, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin
MacroGenicS Inc.
Medarex
MedImmune
Medivation, Inc
Merck & Co.
Merus N.V.
Moderna Therapeutics
Moffitt Cancer Center
MS
NanoString Technologies, Inc.
NEC Corporation
NewLink Genetics
Novartis
Oncothyreon Inc.
Ono Pharmaceutical
Peregrine Pharmaceuticals
Pfizer, Inc.
Plexxikon Inc.
Prima Biomed
Regeneron Pharmaceuticals
Roche
Sandoz
Sanofi
Seattle Genetics, Inc.
Sosei Group Corporation
Surface Oncology
Syndax Pharmaceuticals
Syros Pharmaceuticals, Inc.
TARIS Biomedical LLC
TESARO, Inc.
TetraLogic Pharmaceuticals Corporation
Transgene SA
Western Oncolytics
Xencor
List of Associations Mentioned in the Report
Cancer Research Institute
Central Social Insurance Medical Council
Data Monitoring Committee
Early Access to Medicines Scheme
European Cancer Congress
European Medicines Agency
European Organisation for Research and Treatment of Cancer
MD Anderson Cancer Center
Medicines and Healthcare Products Regulatory Agency
Ministry of Health, Labour, and Welfare
National Cancer Institute
National Institute for Health and Clinical Excellence
QIMR Berghofer Medical Research Institute
University of Pittsburgh
Yamaguchi University
Download sample pages
Complete the form below to download your free sample pages for Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031Related reports
-
North American Molecular Diagnostics (MDx) Market Report 2021-2031
In order to improve health outcomes, molecular diagnostic testing for genetic or pathogenic diseases is necessary to provide easy, fast...Full DetailsPublished: 17 February 2021 -
Cancer Biologics Market Report 2023-2033
The global Cancer Biologics market was estimated to be valued at US$ 115.9 billion in 2023 and is expected to...Full DetailsPublished: 22 June 2023 -
Biologics Market Report 2022-2032
The global biologics market was valued at US$382.85 billion in 2022 and is projected to grow at a CAGR of...Full DetailsPublished: 04 July 2022 -
Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel...Full DetailsPublished: 14 April 2021 -
Precision Cancer Diagnostic Test Market Report 2022-2032
The global precision cancer diagnostic test market was valued at US$14,087 million in 2021 and is projected to grow at...Full DetailsPublished: 08 June 2022 -
Urothelial Cancer Drugs Market Report 2021-2031
Where the Urothelial Cancer Drugs market is heading? If you are involved in this industry you must read this newly...
Full DetailsPublished: 01 January 1970 -
Cancer Biologics Market Report 2021-2031
The global demand for cancer biologics is expected to expand significantly over the projected period, owing to the expanded acceptance...Full DetailsPublished: 04 February 2021 -
Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or...Full DetailsPublished: 01 April 2021 -
Precision Cancer Diagnostic Test Market Report 2024-2034
The global Precision Cancer Diagnostic Test Market is projected to grow at a CAGR of 16.1% by 2034...Full DetailsPublished: 17 January 2024 -
Bile Duct Cancer Drugs Market Report to 2031
Where is the Global Bile Duct Cancer Drug market heading? If you are involved in this sector you must read...
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
